Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VTRS

VTRS - Viatris Inc Stock Price, Fair Value and News

$12.97-0.15 (-1.14%)
Market Closed

33/100

VTRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

33/100

VTRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.69

Target 3M

$12.52

Target 6M

$11.88

VTRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VTRS Price Action

Last 7 days

-0.6%

Last 30 days

4.9%

Last 90 days

25.2%

Trailing 12 Months

15.8%

VTRS RSI Chart

VTRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VTRS Valuation

Market Cap

14.9B

Price/Earnings (Trailing)

-4.05

Price/Sales (Trailing)

1.06

EV/EBITDA

-44.17

Price/Free Cashflow

9

VTRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.69

Target 3M

$12.52

Target 6M

$11.88

VTRS Fundamentals

VTRS Revenue

Revenue (TTM)

14.1B

Rev. Growth (Yr)

0.23%

Rev. Growth (Qtr)

4.96%

VTRS Earnings

Earnings (TTM)

-3.7B

Earnings Growth (Yr)

-235.23%

Earnings Growth (Qtr)

-2.7K%

VTRS Profitability

EBT Margin

-27.25%

Return on Equity

-24.26%

Return on Assets

-9.73%

Free Cashflow Yield

11.11%

VTRS Investor Care

Dividend Yield

3.7%

Dividend/Share (TTM)

0.48

Buy Backs (1Y)

3.50%

Diluted EPS (TTM)

-3.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202514.3B14.1B14.1B0
202415.4B15.2B15.0B14.7B
202315.8B15.6B15.5B15.4B
202217.6B17.2B16.7B16.3B
202113.8B15.6B17.2B17.9B
202011.6B11.7B11.8B11.9B
201900011.5B
201800011.4B
Get all data in R, Python etc through our Historical Stock Data APIs

About Viatris Inc

VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
 CEO
 WEBSITEviatris.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES38000

Viatris Inc Frequently Asked Questions

VTRS is the stock ticker symbol of Viatris Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Viatris Inc is 14.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VTRS's fair value in chart for subscribers.

The fair value guage provides a quick view whether VTRS is over valued or under valued. Whether Viatris Inc is cheap or expensive depends on the assumptions which impact Viatris Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTRS.

As of Wed Jan 28 2026, VTRS's PE ratio (Price to Earnings) is -4.05 and Price to Sales (PS) ratio is 1.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTRS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Viatris Inc has provided -0.131 (multiply by 100 for percentage) rate of return.